FDA approves treatment for wider range of patients with heart failure
Today, the U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults.
Jardiance was originally approved by the FDA in 2014 as a supplement to diet and exercise to improve glucose control in adults with type 2 diabetes.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Diets | Empagliflozin | Endocrinology | Food and Drug Administration (FDA) | Heart | Heart Failure | Jardiance | Nutrition | Pharmaceuticals | Sports Medicine